Pediatric Pneumococcal Meningitis After Introduction of the PCV13 Vaccine

Although rates of PCV13-serotype meningitis have decreased, overall pneumococcal meningitis rates have not changed.

Researchers used data from eight U.S. children's hospitals to compare the epidemiology and clinical outcomes of pneumococcal meningitis (PM) before and after the 2010 introduction of the 13-valent pneumococcal conjugate vaccine (PCV13).

From 2007 to 2013, 1207 children aged ≤18 years were diagnosed with invasive pneumococcal disease, and of these, 173 had PM. The number of PM cases per year did not change after introduction of the vaccine; however, the proportion of invasive pneumococcal disease cases with PM increased significantly from 12% before to 18% after. Although the proportion of PCV13 serotype PM cases decreased from 54% to 27%, serotype 19A (included in the PCV13 vaccine) remained the most common serotype. Of 10 children with the …

Reviewing Author

Katherine Bakes, MD

Disclosures

RoyaltiesEmergency Medicine Secrets (Elsevier)

Grant/Research SupportDepartment of Justice

Editorial BoardsEmergency Medicine Secrets (Elsevier); Rosen’s Emergency Medicine (Elsevier)

Katherine Bakes, MD

Disclosures

RoyaltiesEmergency Medicine Secrets (Elsevier)

Grant/Research SupportDepartment of Justice

Editorial BoardsEmergency Medicine Secrets (Elsevier); Rosen’s Emergency Medicine (Elsevier)

Pediatric Pneumococcal Meningitis After Introduction of the PCV13 Vaccine

Topics

Reviewing Author